Approved, no longer marketed Hormones & metabolism

Lixisenatide

Lixisenatide is a GLP-1 receptor agonist. It is filed in this library under hormones & metabolism, a navigation topic rather than a statement of where it acts. As a regulatory matter it was approved by the FDA but is no longer marketed in the United States.

Regulatory status

Lixisenatide was approved by the FDA, but the product is no longer marketed in the United States.

An approval that has been discontinued is not the same as a drug you can obtain today.

From the FDA label

What Lixisenatide is approved to treat

100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. SOLIQUA 100/33 is a combination of insulin glargine, an insulin analog, and lixisenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: Concomitant use in combination with any other product containing a GLP-1 receptor agonist is not recommended. Not recommended for the treatment of diabetic ketoacidosis. Has not been studied in combination with prandial insulin. Limitations of Use: SOLIQUA 100/33 contains lixisenatide.Quoted from the FDA-approved prescribing information

The evidence

What has actually been published

One source on Lixisenatide, resolved to its journal of record. The title is listed so you can judge the evidence rather than take a summary on trust.

Nearby

Other peptides acting on hormones & metabolism

Start with your own numbers.

Before any compound, the useful question is what your bloodwork already says. The OPTML Score reads a full panel against optimal ranges.

See the OPTML Score

Educational reference only. This page explains what has been published about Lixisenatide. It is not medical advice, it is not a diagnosis, and it carries no dosing information of any kind. OPTML does not offer or supply this compound unless a product page on this site says otherwise.

Treatment decisions are made by a licensed physician after an individual evaluation. Compounded preparations are not FDA-approved or evaluated by the FDA for safety, effectiveness, or quality. Individual results vary.

All 150 peptides